Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

164.22
-6.4700-3.79%
Volume:136.20K
Turnover:22.35M
Market Cap:22.04B
PE:-46.87
High:167.48
Open:164.70
Low:162.54
Close:170.69
52wk High:176.58
52wk Low:53.40
Shares:134.20M
Float Shares:129.78M
Volume Ratio:2.06
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-98.88
PE(LYR):-49.46

Loading ...

Movement Alert|Guardant Health Falls 8.48% in Pre-Market Trading, Pulling Back After FDA Approval-Driven Rally

Market Focus
·
May 22

Movement Alert|Guardant Health Rises 5.01% in Regular Trading, Liquid Biopsy Test Receives FDA Approval

Market Focus
·
May 21

GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026

TIPRANKS
·
May 21

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and OS Therapies Incorporated (OSTX)

TIPRANKS
·
May 21

Movement Alert|Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test

Market Focus
·
May 21

FDA approves Guardant360 Liquid CDx test for Guardant Health

Reuters
·
May 20

FDA Approves New Guardant360 Liquid Cdx, the Largest FDA-Approved Liquid Biopsy Panel With a 100X Expanded Footprint

THOMSON REUTERS
·
May 20

Judge sanctions law firm Quinn Emanuel, citing ethical lapses

Reuters
·
May 20

Guardant Health director Tariq Musa disposes of USD 11,131.36 in shares

Reuters
·
May 20

GH Research Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 19

Guardant Health grants 143,898 RSUs to 267 new employees under inducement plan

Reuters
·
May 19

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 19

Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS)

Simply Wall St.
·
May 18

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)

TIPRANKS
·
May 16

These Analysts Revise Their Forecasts On GH Research After Q1 Results

Benzinga Earnings
·
May 15

GH Research price target raised to $35 from $25 at Cantor Fitzgerald

TIPRANKS
·
May 15

GH Research Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
May 15

GH Research Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 15

Canaccord Genuity Keeps Their Buy Rating on GH Research (GHRS)

TIPRANKS
·
May 15

GH Research price target lowered to $39 from $42 at Citizens

TIPRANKS
·
May 15